Cited by 78Psoriasis: Treatment and PathogenesisNonmelanoma Skin Cancer StudiesTelomeres, Telomerase, and Senescence

Creation of psoriatic plaques: the ultimate tumor suppressor pathway.: A new model for an ancient T‐cell‐mediated skin disease. Viewpoint

Open access
Nickoloff, Brian J.·2001·Journal of Cutaneous Pathology

Abstract

From an oncological and immunological perspective, the T‐cell‐mediated induction of psoriatic plaques should be prone to malignant transformation as the phenotype of psoriatic plaques includes: chronic inflammation, epidermal hyperplasia, prolonged survival and elevated telomerase levels in lesional keratinocytes, as well as angiogenesis, exposure to carcinogens and immunosuppressants. However, conversion of a psoriatic plaque to squamous cell carcinoma is exceedingly rare. This paper explores the possible molecular mechanism for the tumor suppressor pathway in psoriatic lesions, with an emphasis on a putative senescence‐switch involving p16.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1034/j.1600-0560.2001.280201.x

Cites

78 of 78 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A TNF and IFNγ cocktail might provide dominant tumour suppressor activity through cytokine-induced senescence in psoriasis.

    “Here also a TNF and IFNγ cocktail might provide a dominant tumour suppressor activity through cytokine-induced senescence.”

    From Inside and out: the activities of senescence in cancer (2014) · cites this paper as [135]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 12

  1. Nickoloff BJ. The immunological and genetic basis of pso- riasis. Arch Dermatol 1999; 135: 1104.
  2. Hutchinson J. On some examples of arsenic-keratosis of the skin and of arsenic-cancer. Transactions Path Soc-London 1888; 39: 352.
  3. Barker JNWN. Pathophysiology of psoriasis. Lancet 1991; 338: 227.
  4. Weinstein DG, Frost P. Abnormal cell proliferation in pso- riasis. J Invest Dermatol 1968; 50: 254.
  5. Weinstein GD, Van Scott EJ. Autoradiographic analysis of turnover times of normal and psoriatic epidermis. J Invest Dermatol 1965; 45: 257.
  6. Fry L, McMinn RM. Observation on mitosis in psoriatic epi- dermis. Br J Dermatol 1970; 82: 19.
  7. Weinstein GD, Frost P. Methotrexate for psoriasis. Arch Dermatal 1971; 103: 33.
  8. Pena JC, Rudin CM, Thompson CB. A Bcl-x L transgene pro- motes malignant conversion of chronically initiated skin papil- lomas. Cancer Res 1998; 58: 2111.
  9. Hara E, Smith R, Parry D, Tahara H, Stone S, Peters G. Regulation of p16 expression and its implications for cell im- mortalization and senescence. Mol Cell Biol 1997; 16: 859.
  10. Nickoloff BJ, Chaturvedi V, Qin J-Z, Diaz M, Denning MF, Robinson J. Scattered suprabasilar keratinocytes in psoriatic plaques possess a senescent-like phenotype. J Invest Dermatol Abstract 2000; 114: 759.
  11. Lin AW, Barradas M, Stone JD, vanAelst L, Serrano M, Lowe SW. Primitive senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes & Develop 1999; 12: 3005.
  12. Kane CJ, Knapp AM, Mansbridge JN, Hanawalt PC. Trans- forming growth factor-beta 1 localization in normal and psori- atic epidermal keratinocytes in skin. J Cell Physiol 1990; 144: 144.

Cited by

Sorted by citations

Authors
Nickoloff, B. J.
Affiliations
Loyola University Medical Center (US)
Corresponding author
Nickoloff, Brian J.
Venue
Journal of Cutaneous Pathology
Publisher
Wiley
Published
2001-02
Volume
28
Issue
2
Pages
57-64
ISSN
  • 0303-6987 (ISSN-L)
  • 1600-0560
OpenAlex
W1583462410
Cited by
78
References
78
Citations by year
2026: 2 · 2023: 2 · 2022: 1 · 2020: 1 · 2019: 1 · 2016: 3 · 2015: 2 · 2014: 2 · 2012: 4
FWCI
0.79
Type
journal article
Language
en
Open access
Locations
  • Journal of Cutaneous Pathology (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institutes of Health
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
  • Health Sciences › Medicine › Epidemiology › Nonmelanoma Skin Cancer Studies
  • Health Sciences › Medicine › Physiology › Telomeres, Telomerase, and Senescence
Keywords
psoriasis, psoriatic plaques, tumor suppressor pathways, malignant transformation, squamous cell carcinoma, cellular senescence, p16, telomerase, chronic inflammation, epidermal hyperplasia, angiogenesis, carcinogen exposure, immunosuppressants, T cell-mediated inflammation, keratinocytes
MeSH terms
Carcinoma, Squamous Cell, Cell Transformation, Neoplastic, Humans, Models, Biological, Precancerous Conditions, Psoriasis, Skin Neoplasms, T-Lymphocytes, Keratinocytes, Genes, Tumor Suppressor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review